HealthTree Podcast for Multiple Myeloma

HealthTree Podcast for MM
  • 4,9 (18)
  • FORME ET SANTÉ
HealthTree Podcast for Multiple Myeloma

HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.

  1. -12 H

    2024 Mid-Year Myeloma Review with Paul Richardson, MD, Dana Farber Cancer Institute

    Learn about the latest in multiple myeloma advances with Paul Richardson, MD who will cover the recent American Society of Hematology and European Hematology Association meeting findings.

    1 h 10 min

  2. 18 JUIL.

    The Latest in Amyloidosis Care and Research with Morie Gertz, MD, Mayo Clinic

    Dr. Morie Gertz joins the HealthTree Podcast for Multiple Myeloma to share the challenges, treatments and futures of AL amyloidosis and invites amyloidosis patients to join this survey about their diagnosis experience.

    37 min

  3. 15 JUIL.

    Creating a Risk Profile to Personalize Myeloma Care with Ola Landgren, MD, PhD, University of Miami

    Dr. Ola Landgren shares a clinical trial about smoldering myeloma. Join the REVIVE trial study for high-risk smoldering myeloma study here.  He also share about his research partnership with HealthTree on a personalized medicine study that creates a computerized model of risk prediction and treatment recommendations for newly diagnosed patients.  This is a study that is open to all myeloma patients regardless of where they are being treated. The only involvement by patients is to sign a consent form and connect their medical records which requires less than 5 minutes of participation.

    1 h 1 min

  4. 12 MARS

    Using all the Myeloma Tools in the Toolbox with Clifton Mo, MD, Dana Farber Cancer Institute

    Dr. Clifton Mo of Dana Farber Cancer Institue shares a multitude of tools available in the myeloma toolbox. This includes all of the "standard of care" drugs that we are familiar with such as immunomodulators, proteasome inhibitors, steroids, monoclonal antibodies as well as tools in development.  He reviews triplet combo treatment options at first relapse and his preference to use Kyprolis in the mix, especially when given a more aggressive myeloma.  Dr. Mo explains how antibody drug conjugates (ADCs) work and how the first ADC, BLENREP, may be making a comeback. He shares how dexamethasone can be reduced or stopped under certain conditions. He explains BCL-2 inhibitors like venetoclax and how they are making their way through clinical trials.  Dr. Mo describes celmods and how they work and are a promising new class of drugs. He also described how an XPO1 inhibitor called selinexor is being used both with the celmods  and alone as an agent that works well for higher risk myeloma.  This shows myeloma patients how fortunate we are to have these tools available and speaks to the importance of having a myeloma specialist on your team who can help you make treatment decisions. This can be done alone or in partnership with your local oncologist. There is data that shows that having a specialist on year team leads to longer life.

    59 min

  5. 10 FÉVR.

    Alfred Garfall, MD and Bea Razzo, MD on Bispecific Antibodies in Multiple Myeloma

    Learn how bispecific antibodies are being used in multiple myeloma care and how physicians are helping patients manage side effects using new approaches like fixed-duration therapy.

    1 h

  6. 9 JANV.

    The 2024 Myeloma Landscape with Robert Orlowski, MD, PhD, MD Anderson

    The year 2024 brings new promise in multiple myeloma with a wide variety of treatment options avaiable for both newly diagnosed and relapsed/refractory patients. Learn about the progress being made and the very latest in determining risk at diagnosis, strategies for smoldering myeloma patients, optimal treatments for newly diagnosed patients, things to consider at first relapse and beyond. Dr. Robert Orlowski will review advances in CAR T therapies, bispecific antibodies, targeted therapies and combination approaches and clinical trials to watch as the research continues advancing at a rapid pace in myeloma.  Thanks to our episode sponsor, GSK.

    1 h 16 min

  7. 27/10/2023

    Today's CAR T Options in Multiple Myeloma Care with Luciano Costa, MD, UAB

    CAR T therapy is a highly effective treatment for myeloma patients, even in highly relapsed multiple myeloma. In today's show we will hear from Luciano Costa, MD of the University of Burmingham who will do a deep dive into CAR T therapy in multiple myeloma to discuss how CAR T availability is improving, how CAR T is being tested in earlier lines of therapy, side effects to consider, new CAR T targets, combo CAR Ts, maintenance therapy post-CAR T, open CAR T clinical trials and various new forms CAR T variants like NK CAR Ts. Join us for this important show on one of the most impressive therapies ever developed in myeloma!  Thanks to our episode sponsor,  Menarini Silicon Biosystems

    1 h 2 min

  8. 22/09/2023

    Multiple myeloma mid-year progress with Dr. Paul Richardson of Dana Farber

    Dr. Paul Richardson of the Dana Farber Cancer Institute shares a mid-year myeloma review of ASCO, EHA and upcoming International Myeloma Society findings of the fast-moving research being performed in myeloma. Updates will include the expanding world of bispecific antibodies that include one FDA-approved drug and anticipated approvals for two new bispecific antibodies. He will also discuss exciting results from CAR T cinical trials,  CAR T newcomers, sequencing preferences, BCMA targeted therapies, new therapy targets in myeloma, MRD advances, blood-based testing, clinical trials end points and more.  Thanks to our episode sponsor, Karyopharm.

    1 h 4 min
Tout afficher (171)

4,9
sur 5
18 notes

À propos

HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.

Informations

  • Création
    HealthTree Podcast for MM
  • Années d’activité
    2013 - 2024
  • Épisodes
    171
  • Classification
    Tous publics
  • Copyright
    © HealthTree Podcast for MM
  • Site web de l’émission
    HealthTree Podcast for Multiple Myeloma

Vous aimeriez peut‑être aussi

Pour écouter des épisodes au contenu explicite, connectez‑vous.

Recevez les dernières actualités sur cette émission

Connectez‑vous ou inscrivez‑vous pour suivre des émissions, enregistrer des épisodes et recevoir les dernières actualités.
Choisissez un pays ou une région

Afrique, Moyen‑Orient et Inde

Asie‑Pacifique

Europe

Amérique latine et Caraïbes

États‑Unis et Canada